Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT01002352 Active, not recruiting - Obesity Clinical Trials

Bariatric Outcomes Longitudinal Database (BOLD)

BOLD
Start date: June 2007
Phase: N/A
Study type: Observational

The primary purpose of the Bariatric Outcomes Longitudinal Database (BOLD) study is to assess the mid- and long-term outcomes of bariatric surgeries and to analyze the relationship between these outcomes and 1) patient demographics and comorbidities, 2) clinical and surgical characteristics, and 3) pre-operative, peri-operative and post-operative care and treatment.

NCT ID: NCT00985101 Active, not recruiting - Diabetes Mellitus Clinical Trials

Study of Cellular Impairments Involved in Diabetic Complications

diabmito I
Start date: April 2010
Phase: N/A
Study type: Observational

The purpose of this study is to examine if an early detectable dysfunction in a cellular component (mitochondria) may predict complications in diabetes mellitus.

NCT ID: NCT00935805 Active, not recruiting - Diabetes Mellitus Clinical Trials

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

Start date: July 2006
Phase: N/A
Study type: Observational

The aim of this study is to to analyze if it is possible to reach the goals of HbA1c <7.0% and blood pressure <= 130/80 mm Hg in a cohort of patients with type 2 diabetes attending a primary care unit, using ony those resources available at the unit, and provided by the Brazilian National Health System. It is an open label, observational study, with a duration of 4-6 years. Patients attending a primary care outpatient facility will be sequentially included in the study provided they give consent. They will be followed on a monthly basis by a team of physicians and nurses. Glucose, A1c, Blood PRessure will be the outcomes.

NCT ID: NCT00929812 Active, not recruiting - Obesity Clinical Trials

Glucagon Modulation of Ghrelin Secretion

Start date: June 2006
Phase: Phase 3
Study type: Interventional

As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol release in humans. Recently, it has been shown that glucagon induces a remarkable decrease in ghrelin levels. The mechanisms underlying this effect are unclear and the role of changes in glucose, insulin, glucagon-like peptide-1 (GLP-1) and catecholamines are widely discussed. The aim of the present study is to further evaluate the effect of glucagon on ghrelin secretion and the possible role of the above mentioned factors in mediating this effect.

NCT ID: NCT00926744 Active, not recruiting - Hypertension Clinical Trials

Nutrition and Exercise Intervention Study

NEXIS
Start date: April 2006
Phase: N/A
Study type: Interventional

The purpose of the present study was to clarify the effects of increase in physical activity on incidence and surrogate marker of cardiovascular diseases. The working hypothesis of the present study was that the physical activity to satisfy the Japanese guideline of Ministry of Health, Labour and Welfare is effective for the primary prevention of the lifestyle-related disease.

NCT ID: NCT00877864 Active, not recruiting - Diabetes Mellitus Clinical Trials

Diabetes Exercise and Lifestyle Trial

DEAL
Start date: February 2010
Phase: Phase 0
Study type: Interventional

The objective of this study is to determine the effects of supervised combined aerobic and resistance training, and the effects of stage-matched written materials delivered by mail or internet, alone or in combination, on glycemic control as reflected in A1C (glycated hemoglobin).

NCT ID: NCT00863967 Active, not recruiting - Stroke Clinical Trials

Early Detection of Arteriosclerosis

Start date: October 2003
Phase: N/A
Study type: Observational

Arteriosclerosis is a common chronic disease with well known risk factors like diabetes mellitus, hypertension, dyslipidemia, adipositas and smoking, leading to severe complications like myocardial infarction, stroke or peripheral arterial occlusive disease. In addition to life-style factors there is also a genetic predisposition to develop complicated atherosclerosis. Objective: Improve individual risk prediction by clinical phenotyping and genotyping.

NCT ID: NCT00850135 Active, not recruiting - Clinical trials for Diabetes, Gestational

Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Diabetic pregnant patients are at risk for adverse pregnancy outcomes, including larger than expected fetuses and unplanned operative deliveries, due to elevated blood glucose levels. the one-hour glucola test is currently used to screen pregnant patients for gestational diabetes. This involves ingesting a 50-gram glucose load, followed by a blood test one hour later. We wish to compare 7-day continuous glucose monitoring to the one-hour glucola test, and determine which one correlates better with adverse pregnancy outcomes as well as which one more accurately identifies patients at risk for adverse pregnancy outcomes.

NCT ID: NCT00838344 Active, not recruiting - Diabetes Clinical Trials

The Medication Adherence Program

MAP
Start date: April 2008
Phase: N/A
Study type: Interventional

In this study, the investigators will evaluate the impact of a Medication Adherence Program (MAP), a systematic telephone call to patients who are overdue for refills, to assess individual reasons or barriers to refilling prescribed DM medicines, discuss diabetes care progress, and provide intervention to resolve any barriers to taking prescribed medicines. The hypothesis for the study is that personalized telephone follow-up by a pharmacist will assist people who have missed refilling their prescriptions in taking diabetes medicines by resolving medication adherence challenges. Following randomization, the intervention will be offered to patients of four Seattle-area Safeway Pharmacies, Inc, who are overdue for prescribed DM medicine refills by at least 6 days. Control subjects will receive usual pharmacy care at the participating Safeway pharmacies as a comparison. The study will provide medication adherence support to intervention subjects for 12 months following enrollment with the goal of improving medication refilling and persistence.

NCT ID: NCT00824499 Active, not recruiting - Diabetes Type 2 Clinical Trials

Development, Implementation and Evaluation of a Complex Regional Intervention for Type 2 Diabetes: Diabetes Project Aalst

DPA
Start date: February 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether regional implementation of shared care with respect to type 2 diabetes is feasible, effective and cost-effective.